Engineered Exosomes with Specific RNA Mutations for Molecular Reference Standards
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for cancer diagnostics and treatment monitoring using exosomal nucleic acid biomarkers are limited due to the lack of exosome molecular reference standards, which hinders assay development, performance validation, and interpretation of results.
Innovation Solution
A method for producing exosomes containing RNA with specific mutations using genome editing enzymes like CRISPR/Cas nuclease, allowing for the generation of engineered cell lines that secrete exosomes with defined RNA cargo, which can be used as molecular references for assay development and quality control.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If exosomes are isolated from patient biofluids for molecular reference standards, then the reference standards reflect real clinical samples, but the lack of standardized production methods leads to variability in physical properties and genomic composition
Solution Approach 1:
The patent applies preliminary action by pre-modifying the genome of producer cells using CRISPR/Cas9 technology before exosome production. Specific mutations (e.g., EGFR T790M, KRAS G12D) are introduced into the cell line, ensuring that all subsequently produced exosomes consistently carry these defined genetic alterations. This pre-establishment of genetic characteristics in the producer cell line guarantees reproducible genomic composition in the exosome reference standards, resolving the variability issue while maintaining clinical relevance.
2Adaptability or versatility
If genome editing is used to create cells with specific mutations, then exosomes with defined RNA cargo can be produced for assay validation, but the complexity of genome editing procedures increases
Solution Approach 1:
The patent employs copying by creating engineered cell lines that serve as stable templates for exosome production. Once a cell line is successfully edited with desired mutations (e.g., HCT116 cells with EGFR mutations), this engineered cell line can be propagated and used to produce batches of exosomes with identical, defined RNA cargo. This copying approach eliminates the need to repeatedly perform complex genome editing for each exosome batch, reducing procedural complexity while maintaining the ability to produce exosomes with specific mutations for various assay validation needs.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables the creation of reliable exosome molecular references that mimic the physical properties and genomic composition of patient-derived exosomes, facilitating the validation of exosome-based clinical assays and improving diagnostic and therapeutic applications.
Implementation Method 1
generating a cell comprising a mutation of a gene by using a genome editing enzyme
Data Source
AI summary
Provided herein are methods for producing exosomes that contain RNA transcribed from a specific mutant gene or a transgene. In one embodiment, the method comprises the steps of: generating a cell comprising a mutation of a gene by using a site-specific nuclease; culturing the cell in a medium that allows the cell to secrete to the medium an exosome containing an RNA transcribed from the gene and comprising the mutation; and collecting the medium that contains the exosome. The exosomes generated can be used as reference material or therapeutic delivery device.